psalexa
logo

Meniere’s Disease Therapeutics Pipeline Analysis

Meniere’s Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11240
Available Format:

Meniere's disease is a type of disorder that causes congestion in the ear, hearing loss, dizziness (also known as vertigo), and ringing in the ears (also known as tinnitus). In some cases, patients fall due to severe vertigo and such sort of attack called drop attacks. It has been observed that meniere’s disease occurs mostly between 40 to 60 years of age. Meniere's disease is caused by fluid build-up in the labyrinth which comprises of two parts, including the membranous labyrinth and bony labyrinth. Membranous labyrinth is filled with a fluid known as endolymph. Building-up of endolymph causes anomalies in hearing signals and normal balance which further leads to vertigo. Sound Pharmaceuticals, Inc. is in the process of developing SPI-1005 as an antioxidant for the treatment of meniere’s disease. Otonomy, Inc. is in the process of developing OTIVIDEX (dexamethasone) as a glucocorticoid receptor agonist for the treatment of meniere’s disease. Some of the companies having the pipeline of meniere’s disease include Sound Pharmaceuticals, Inc., Otonomy, Inc., Xenon Pharmaceuticals Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry